ETNB - Liver drug developers outperform as U.S. awaits first NASH drug
2024-03-13 13:29:04 ET
More on Madrigal Pharmaceuticals
- Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown
- Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade)
- Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential
- Citi starts Madrigal at buy, cites upcoming FDA decision on NASH drug
- Madrigal gains as NASH therapy undergoes EU review